Binding of heparan sulfate to human cystatin C modulates inhibition of cathepsin L: Putative consequences in mucopolysaccharidosis.
Glycosaminoglycan
Inhibitor
Lung
Molecular dynamic
Protease
Journal
Carbohydrate polymers
ISSN: 1879-1344
Titre abrégé: Carbohydr Polym
Pays: England
ID NLM: 8307156
Informations de publication
Date de publication:
01 Oct 2022
01 Oct 2022
Historique:
received:
20
04
2022
revised:
30
05
2022
accepted:
11
06
2022
entrez:
7
7
2022
pubmed:
8
7
2022
medline:
12
7
2022
Statut:
ppublish
Résumé
Mucopolysaccharidoses (MPS) are a group of rare lysosomal storage diseases characterized by glycosaminoglycan (GAG) accumulation causing progressive multi-organs dysfunction and ultimately severe cardio-respiratory damages. Human cystatin C (hCC), a potent inhibitor of cysteine cathepsins, plays an important role in respiratory diseases. However, its regulation remained unknown in MPS. Herein, elevated hCC levels were measured in respiratory specimens from MPS-I, -II, and -III patients and were significantly correlated with severe respiratory symptoms (rs = 0.7173). Heparan sulfate (HS), a prominent GAG, dampened its inhibitory activity toward cathepsin L in a dose-dependent manner. HS and HS-oligosaccharides bound tightly hCC, in combination with a secondary structure rearrangement. Molecular modeling studies identified three HS binding regions in hCC, including the N-terminus, which is crucial in the inhibition of cathepsins. Impairment of inhibitory potential of hCC may reflect abnormal regulation of proteolytic activity of cathepsin L in lung, ultimately contributing to the severity of MPS.
Identifiants
pubmed: 35798429
pii: S0144-8617(22)00639-7
doi: 10.1016/j.carbpol.2022.119734
pii:
doi:
Substances chimiques
Cystatin C
0
Glycosaminoglycans
0
Heparitin Sulfate
9050-30-0
Cathepsin L
EC 3.4.22.15
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
119734Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.